Gerd Maass
Amministratore Delegato presso Siloanlagen Achberg Holding GmbH
Profilo
Mr. Gerd Maass is a Managing Director at Siloanlagen Achberg Holding GmbH.
He is on the Board of Directors at ETHRIS GmbH.
Posizioni attive di Gerd Maass
| Società | Posizione | Inizio |
|---|---|---|
Siloanlagen Achberg Holding GmbH
 Siloanlagen Achberg Holding GmbH Financial ConglomeratesFinance Siloanlagen Achberg Holding GmbH is an investment holding private company. The company is based in Achberg, Germany. The CEO of the German company is Gerd Maass. | Amministratore Delegato | - |
ETHRIS GmbH
 ETHRIS GmbH Miscellaneous Commercial ServicesCommercial Services ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Siloanlagen Achberg Holding GmbH
Siloanlagen Achberg Holding GmbH Financial ConglomeratesFinance Siloanlagen Achberg Holding GmbH is an investment holding private company. The company is based in Achberg, Germany. The CEO of the German company is Gerd Maass. | Finance |
ETHRIS GmbH
ETHRIS GmbH Miscellaneous Commercial ServicesCommercial Services ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Gerd Maass
